Patent application number | Description | Published |
20090149438 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 06-11-2009 |
20090163465 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 06-25-2009 |
20090163467 | New compounds - The present invention encompasses compounds of general formula (1) | 06-25-2009 |
20090203683 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM - A compound of formula (I) | 08-13-2009 |
20090318480 | METHOD FOR TREATING CANCER HARBORING EGFR MUTATIONS - The present invention relates to a method of treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour. | 12-24-2009 |
20100010023 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - A compound of general formula I | 01-14-2010 |
20100069414 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM - The present invention relates to bicyclic heterocycles of general formula | 03-18-2010 |
20100144706 | Compounds - The present invention encompasses compounds of general formula (1) wherein R | 06-10-2010 |
20100222331 | NEW COMPOUNDS - The present invention encompasses compounds of general Formula (1) wherein R | 09-02-2010 |
20110039863 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 02-17-2011 |
20110046168 | METHODS OF TREATING DISEASES USING QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - A compound of general formula I | 02-24-2011 |
20110086842 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 04-14-2011 |
20110136826 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 06-09-2011 |
20110251174 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS - The present invention encompasses compounds of general formula (1) | 10-13-2011 |
20120107304 | Combination therapy in treatment of oncological and fibrotic diseases - The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of a cell signalling and/or angiogenesis inhibitor in conjunction with an Aurora kinase inhibitor. | 05-03-2012 |
20120157472 | METHOD FOR TREATING COLORECTAL CANCER - The present invention relates to a method of treating patients suffering from colorectal cancer characterized by coadministration of BIBF 1120 and BIBW 2992, wherein in said method BIBF 1120 is administered according to a continuous daily regimen and BIBW 2992 is administered according to a weekly alternating on-off regimen, pharmaceutical compositions and kits suitable for this method as well as their preparation. | 06-21-2012 |
20120294867 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER - The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m | 11-22-2012 |
20120329778 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM - The present invention relates to bicyclic heterocycles of general formula | 12-27-2012 |
20130004481 | ANTICANCER THERAPY - The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein. | 01-03-2013 |
20130012465 | BIBW 2992 FOR USE IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER - The present invention relates to a method of treating patients suffering from triple negative breast cancer comprising administration of an effective amount of the irreversible EGFR/HER1 and HER2 inhibitor BIBW 2992 (1) to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent (2), in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery. | 01-10-2013 |
20130178487 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES - The present invention relates to the use of quinazolines of formula (I), | 07-11-2013 |
20130281429 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS - The present invention encompasses compounds of general formula (1) | 10-24-2013 |
20130289014 | Combination therapy in treatment of oncological and fibrotic diseases - The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of a cell signalling and/or angiogenesis inhibitor in conjunction with an Aurora kinase inhibitor. | 10-31-2013 |
20140057898 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 02-27-2014 |
20140194442 | ANTICANCER THERAPY - The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein. | 07-10-2014 |
20140199298 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS - The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of:
| 07-17-2014 |
20140341926 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER - The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m | 11-20-2014 |